<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03514511</url>
  </required_header>
  <id_info>
    <org_study_id>LP0145-1315</org_study_id>
    <nct_id>NCT03514511</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate the safety and tolerability of LEO
      138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.

      The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics
      following administration of LEO 138559 to healthy subjects and subjects with moderate to
      severe atopic dermatitis.

      Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen
      per subject).

      Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose
      regimens of LEO 138559 (one dose regimen per subject).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of LEO 138559 - numbers of subjects with adverse events</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of LEO 138559 - number of adverse events</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of LEO 138559 - number of local site reactions</measure>
    <time_frame>Day 1 to Day 120</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 1) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 2) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 3) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 4) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 5) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 6) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 7) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 8) or LEO 138559 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 138559 (dose regiment 9) or LEO 138559 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 138559</intervention_name>
    <description>LEO 138559 is a compound in development at LEO Pharma A/S</description>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 138559 placebo</intervention_name>
    <description>LEO 138559 placebo</description>
    <arm_group_label>Cohort 1 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 2 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 3 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 4 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 5 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 6 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 7 in healthy subjects</arm_group_label>
    <arm_group_label>Cohort 8 in subjects with atopic dermatitis</arm_group_label>
    <arm_group_label>Cohort 9 in subjects with atopic dermatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For healthy subjects and subjects with atopic dermatitis:

          -  Males and females without childbearing potential.

          -  Age between 18 and 55, inclusive.

          -  Body mass index between 18 and 32 kg/m2, inclusive.

          -  Healthy apart from atopic dermatitis for the subjects presenting the disease.

        For subjects with atopic dermatitis only:

          -  History of atopic dermatitis for more than 6 months.

          -  Female subjects with childbearing potential and male subjects with female partners
             with childbearing potential using highly effective contraception from start of the
             trial and until a period after the last administered dose of trial drug.

        Exclusion Criteria:

        For healthy subjects and subjects with atopic dermatitis:

          -  Any significant disease detected prior to enrolment.

          -  Subjects who are still participating in a clinical trial or who have participated in a
             clinical trial within 3 months prior to enrolment or within 5 times of the half-life
             of the experimental therapy, whichever is longer.

          -  Skin diseases that may interfere with the diagnosis of atopic dermatitis or assessment
             of the treatment.

          -  Use of tanning beds or phototherapy within 6 weeks prior to enrolment.

          -  Subjects with atopic dermatitis requiring more than 3 bleach baths from 4 weeks prior
             to screening until end of trial.

          -  Blood pressure or pulse rate outside of the normal range.

        For subjects with atopic dermatitis only:

          -  Initiation of treatment of atopic dermatitis with prescription emollients during the
             screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEO Pharma A/S</last_name>
    <phone>(+1) 877-557-1168</phone>
    <email>disclosure@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

